Karyopharm Therapeutics (NASDAQ:KPTI) Announces Quarterly Earnings Results

Karyopharm Therapeutics (NASDAQ:KPTI) announced its quarterly earnings data on Thursday. The company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95), FiscalAI reports. The business had revenue of $33.43 million for the quarter, compared to the consensus estimate of $32.19 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

• Myelofibrosis sNDA remains on track for August 2026 under the FDA’s Accelerated Approval pathway, supported by rapid, deep, and sustained spleen-volume responses in the SENTRY trial and constructive FDA discussions.
• If approved, selinexor plus ruxolitinib could become the first approved combination therapy for myelofibrosis, with a potential launch as early as the first quarter of 2027 and estimated U.S. peak annual revenue of approximately $1 billion.
• Liquidity remains a significant risk: Karyopharm had $65.4 million in cash and investments at quarter-end, expects funding only into September 2026, and faces a $16.8 million term-loan payment on September 10 that could trigger a covenant breach without new financing, a waiver, or a strategic transaction.
• The company is reducing investment in endometrial cancer after the XPORT-EC-042 Phase III trial failed to reach statistical significance, while focusing resources on myelofibrosis and multiple myeloma; XPOVIO U.S. revenue nevertheless rose to $30.8 million from $29.7 million year over year.

Karyopharm Therapeutics Stock Down 3.2%

Shares of NASDAQ KPTI traded down $0.07 during midday trading on Thursday, hitting $1.97. The company had a trading volume of 1,129,125 shares, compared to its average volume of 974,032. The firm has a market capitalization of $44.53 million, a price-to-earnings ratio of -0.13 and a beta of 0.89. Karyopharm Therapeutics has a twelve month low of $1.80 and a twelve month high of $10.99. The business has a 50-day simple moving average of $7.75 and a two-hundred day simple moving average of $7.93.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Royal Bank Of Canada reiterated an “outperform” rating and set a $16.00 price target on shares of Karyopharm Therapeutics in a research note on Tuesday, July 21st. HC Wainwright lowered Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a report on Friday, July 31st. Piper Sandler cut their target price on Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Robert W. Baird cut Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price target for the company. in a report on Friday, July 31st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $11.50.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC raised its holdings in Karyopharm Therapeutics by 100.0% during the fourth quarter. ADAR1 Capital Management LLC now owns 50,000 shares of the company’s stock worth $368,000 after purchasing an additional 25,000 shares during the last quarter. Trexquant Investment LP purchased a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at $307,000. Jump Financial LLC purchased a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at $396,000. Royal Bank of Canada raised its stake in shares of Karyopharm Therapeutics by 761.3% during the 4th quarter. Royal Bank of Canada now owns 58,000 shares of the company’s stock worth $427,000 after buying an additional 51,266 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Karyopharm Therapeutics by 27.2% during the 4th quarter. State Street Corp now owns 58,942 shares of the company’s stock worth $434,000 after buying an additional 12,600 shares during the last quarter. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.